No Data
No Data
No Data
No Data
No Data
Mengke Pharmaceutical: Revenue of about 33.02 million yuan in the first quarter of 2024 increased 91.10% year-on-year
SHANGHAI, April 28, 2024/PRNewswire/ -- On the evening of April 25, the company released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 33.0161,000 yuan, an increase of 91.10% over the previous year; realized net profit to mother of 102.1366 million yuan; and total R&D investment of 84.646,900 yuan, an increase of 94.73% over the previous year. Evidence-based medical research continues to advance, accelerating the release of clinical potential. The company's first commercial product, contizolamide tablets, is a new generation of oxazolidinone antimicrobials independently designed and developed by the company, which can be used to treat complex skin and soft tissues
PR NewswireApr 27 23:03 ET
Mengke Pharmaceutical (688373.SH) announced first-quarter results with a net loss of 102 million yuan
Mengke Pharmaceutical (688373.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...
Zhitong FinanceApr 25 04:06 ET
Mengke Pharmaceutical (688373.SH): The ban on 2.631 million restricted shares was lifted on April 23
Gelonghui, April 12丨Mengke Pharmaceutical (688373.SH) announced that the total number of shares in circulation during the current stock listing was 2.631 million shares. The stock listing and circulation date is April 23, 2024.
Gelonghui FinanceApr 12 06:04 ET
Mengke Pharmaceutical (688373.SH): Shareholders, directors and executives completed a plan to increase their shareholding in the company
Gelonghui, April 12, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 11, 2024, the increase holder had accumulated 569,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.087% of the company's total share capital, with a total increase of 2,951,649 yuan. The implementation of this holdings increase plan has been completed. Entities of this increase include some shareholders, directors and senior management of 5% or more of the company, including: MICURX (HK) LIMITED (hereinafter referred to as “Mengke Hong Kong”), the chairman of the company
Gelonghui FinanceApr 12 06:03 ET
What Shanghai MicuRx Pharmaceutical Co., Ltd.'s (SHSE:688373) 26% Share Price Gain Is Not Telling You
Shanghai MicuRx Pharmaceutical Co., Ltd. (SHSE:688373) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recen
Simply Wall StApr 9 19:16 ET
Mengke Pharmaceutical (688373.SH): Relevant shareholders increased their total shares by 0.04%
Gelonghui, April 8, 丨 Mengke Pharmaceutical (688373.SH) announced that as of April 8, 2024, the increase holder had accumulated 269,800 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.04% of the company's total share capital. The total amount of increase in holdings was 13.297.39 million yuan, which has exceeded 50% of the lower limit of 500,000 shares in this increase plan. The implementation of this holdings increase plan has not yet been completed, and the entities that have increased their holdings will continue to implement the holdings increase in accordance with the holdings increase plan. The entities of this increase in holdings include some shareholders, directors and senior management personnel of 5% or more, including: Company 5
Gelonghui FinanceApr 8 06:45 ET
No Data
No Data